Cover Image

到定量噴霧吸入器 (MDI) :2020年預測

Metered Dose Inhalers to 2022

出版商 Greystone Research Associates 商品編碼 338588
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
到定量噴霧吸入器 (MDI) :2020年預測 Metered Dose Inhalers to 2022
出版日期: 2015年09月01日 內容資訊: 英文

本報告提供定量噴霧吸入器 (MDI) 市場相關調查分析、市場趨勢、技術要素、性能要素、產品評估與分析、治療藥市場分析、市場資料與預測、市場要素、主要企業等相關的系統性資訊。



  • 設備與製劑
  • 市場區隔和功效
  • 競爭技術
  • 確立的治療標的
  • 人口統計和成長率
  • 推動市場要素
  • 危險因素


  • 設備策略
  • 設備特性
  • 設計參數


  • 用量遞送和患者的訓練
  • 呼吸工作
  • 用量和劑量
  • 並用藥


  • 品牌藥的吸入器
  • 非專利DPI吸入器
  • 並用藥的吸入器


  • 氣喘
    • 成人氣喘
    • 兒童氣喘
    • COPD


  • 臨床試驗
  • 專利技術
  • 管理護理


Product Code: MDJ782K

Small Improvements Keeping MDIs Relevant

Metered dose inhalers have been around for more than thirty years, and while the underlying technology is relatively straightforward and mature, device developers and their inhaled drug partners have been able to add improvements and/or new features that address MDI limitations and advance ease-of-use. Because of the underlying physiology of the human respiratory system, inhaled drug pharmacodynamics, and marked variations in the use of inhalers across patient populations, inhaler design presents unique challenges to device developers. Recent improvements in the control of the inspiry event have reduced the need for add-on devices designed to help regulate patient administration. Growth in upper airway therapeutics will help to push MDI unit demand to high single digits between now and the end of the decade.

The value we provide to our clients and subscribers is best illustrated by our ability to consistently provide strategic direction and market knowledge that contributes to their tactical and strategic decision process.

What You Will Learn

  • What inhalable drugs are supplied in MDIs, how are they marketed, what are the device specifics, and who markets them?
  • What inhalable MDI products are in late stage development, who are the developers, and what indications are they targeting?
  • What are the major factors driving metered dose inhaled drug/device demand?
  • What is the size of the market today, who are the market share leaders, and what will the market share be in 2022?
  • How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
  • What are the essential design factors, material selection issues, technologies and market development issues MDI products?
  • What are the significant economic, technology, and regulatory factors affecting the market for MDIs?

Market-driven Product Strategies

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.

Tailored Research

As technology and products evolve, the level of precision in management decisions required to enable effective company performance is increasing. Such precision cannot be achieved without timely and accurate data about the company's macroscopic operating environment. The information that you and your management team require to execute your business and market strategies is unique to your organization and business model. This is why - in addition to the multi-client reports you will find on our site - we offer client-specific research services that start with customer-defined needs and culminate in assessments and analysis that answer the questions that represent risk to your business strategy. To discuss Greystone's Customer Defined Research services, we invite you to contact us.

‘The pediatric market is an important segment for URT therapeutics. In 2013, 9% of children in the United States were considered asthmatic. Nine million U.S. children under 18 have been diagnosed with asthma at some point in their lifetime. Approximately 40% of children who have asthmatic parents will develop asthma. Because of potential side effects, regulatory approval and prescribing options for pediatric asthma pose unique challenges for drug developers and caregivers.’

Table of Contents

Executive Summary

Inhaled Drug Delivery Market Dynamics

  • Devices and Formulations
  • Market Segments and Indications
  • Competing Technologies
  • Established Therapeutic Targets
  • Demographics and Growth
  • Market Drivers
  • Risk Factors

MDI Technology Factors

  • Device Strategies
  • Device Characteristics
  • Design Parameters

MDI Performance Factors

  • Dose Delivery and Patient Training
  • Breath actuation
  • Doses and Dose Counters
  • Dual (Combination) Drug MDIs

MDI Product Assessments and Analysis

  • Branded Drug Inhalers
  • Generic DPI Inhalers
  • Combination Drug Inhalers

Therapeutic Market Analysis, Market Data and Forecasts

  • Asthma
    • Adult Asthma
    • Pediatric Asthma
    • COPD

Market Factors

  • Clinical Trials
  • Proprietary Technology
  • Managed Care

Company Profiles

Back to Top